Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement

Abstract

Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3–5% of non–small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens the door to new treatment strategies.

The acid-sensing nociceptor TRPV1 controls breast cancer progression in bone via regulating HGF secretion from sensory neurons

“…Role of HGF derived from SNs in the 4T1 BC colonization in tibiae, and lung metastasis from tibiae, and induction of BCIBP in the 4T1 BC mice To validate the role of HGF in 4T1 BC progression in bone and metastasis to lung in the 4T1 BC mice, we determined the effects of crizotinib, a small compound of c-Met/ALK tyrosine kinase inhibitor, which has been shown to have bene cial effects in patients with non-small cell lung cancer 43 and breast cancer 44 . Our results demonstrated that oral administration of crizotinib signi cantly inhibited the development of osteolytic lesions associated with 4T1 BC colonization in tibiae (Fig.…”

Clinical Efficacy of Crizotinib as the First-Line Therapy of Advanced Non-Small-Cell Lung Carcinoma with ROS-1 Rearrangement: A Systematic Review

“…Crizotinib is a drug designed to treat NSCLC with ALK mutation and has shown improvement in previous studies [10]. Crizotinib is approved as a therapy option for ROS-1 rearrangement in many countries, especially in advanced non-small-cell lung carcinoma [11,12].…”